FSHD patient-derived LCLs express endogenous DUX4, together with early and late DUX4 target genes (identified from exogenous DUX4 expression in myogenic cells) more robustly than FSHD myoblasts or differentiated myotubes. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.